image: The ARDD Meeting 2022 will be hosted on August 29 - September 2, 2022 view more
Credit: Insilico Medicine Hong Kong Limited
March 16, 2022, the Scheibye-Knudsen Lab, University of Copenhagen and Deep Longevity are excited to reveal the speakers for the 9th Aging Research & Drug Discovery Meeting, the largest scientific academic, and industry conference that will transpire on August 29 - September 2, 2022 on-site at the Ceremonial Hall, University of Copenhagen, and online.
According to the United Nations, the proportion of people aged over 65 now outnumber children younger than 5. The enormous growth in the elderly population is posing a significant healthcare challenge to societies worldwide. New sweeping interventions for reducing age-associated morbidities and frailty will undoubtedly be a key to reduce the health- and socioeconomic challenges that come with an aging society. Again this year we have an incredibly exciting program with global thought-leaders sharing their latest insights into aging and how we target the aging process ensuring everyone lives a healthier and longer life.
“Despite pandemics and the shocking conflict on the European continent, the ARDD 2022 conference will be held in person at the University of Copenhagen. We are extremely excited about the program and the possibility of meeting friends and colleagues outside of zoom. This year we are maintaining our focus on young scientists who will be the future of our field and we have a large number of speaker slots for these rising stars." said Morten Scheibye-Knudsen, MD, Ph.D., University of Copenhagen.
“Many credible biopharmaceutical companies are now prioritized aging research for early-stage discovery or therapeutic pipeline development. It is only logical to prioritize therapeutic targets that are important in both aging and age-associated diseases. The patient benefits either way. The best place to learn about these targets is ARDD, which we organize for nine years in a row. This conference is now the largest in the field and is not to be missed”, said Alex Zhavoronkov, Ph.D., founder and CEO of Insilico Medicine and Deep Longevity.
“Aging research is growing faster than ever on both academia and industry fronts. The ARDD meeting unites experts from different fields and backgrounds, sharing with us their latest groundbreaking research and developments. Our last ARDD meeting took place as a hybrid meeting and was a great success and we will repeat this model for ARDD 2022. ” said Daniela Bakula, Ph.D., University of Copenhagen
For further information, images or interviews, please contact:
ardd@insilico.com
About Scheibye-Knudsen Lab
In the Scheibye-Knudsen lab we use in silico, in vitro and in vivo models to understand the cellular and organismal consequences of DNA damage with the aim of developing interventions. We have discovered that DNA damage leads to changes in certain metabolites and that replenishment of these molecules may alter the rate of aging in model organisms. These findings suggest that normal aging and age-associated diseases may be malleable to similar interventions. The hope is to develop interventions that will allow everyone to live healthier, happier and more productive lives.
About Deep Longevity
Deep Longevity has been acquired by Edurance RP (SEHK:0575.HK), a publicly-traded company. Deep Longevity is developing explainable artificial intelligence systems to track the rate of aging at the molecular, cellular, tissue, organ, system, physiological, and psychological levels. It is also developing systems for the emerging field of longevity medicine enabling physicians to make better decisions on the interventions that may slow down, or reverse the aging processes. Deep Longevity developed Longevity as a Service (LaaS)© solution to integrate multiple deep biomarkers of aging dubbed "deep aging clocks" to provide a universal multifactorial measure of human biological age. Originally incubated by Insilico Medicine, Deep Longevity started its independent journey in 2020 after securing a round of funding from the most credible venture capitalists specializing in biotechnology, longevity, and artificial intelligence. ETP Ventures, Human Longevity and Performance Impact Venture Fund, BOLD Capital Partners, Longevity Vision Fund, LongeVC, co-founder of Oculus, Michael Antonov, and other expert AI and biotechnology investors supported the company. Deep Longevity established a research partnership with one of the most prominent longevity organizations, Human Longevity, Inc. to provide a range of aging clocks to the network of advanced physicians and researchers. https://longevity.ai/
About Endurance RP (SEHK:0575.HK)
Endurance RP is a diversified investment group based in Hong Kong currently holding various corporate and strategic investments focusing on the healthcare, wellness and life sciences sectors. The Group has a strong track record of investments and has returned approximately US$298 million to shareholders in the 21 years of financial reporting since its initial public offering. https://www.endurancerp.com/